Author name: abldadmin

https://www.einpresswire.com/article/913010661/abl-diagnostics-unveils-next-generation-hiv-genotyping-innovation-with-the-industry-s-broadest-portfolio

https://www.abldiagnostics.com/wp-content/uploads/2026/05/P190.pdf

Official Presentation of the DeepChek® HPV Messenger RNA Genotyping Assay Webinar from June 26, 11h00 CET / Paris time https://ablsa-my.sharepoint.com/:f:/p/matthieu_barralon/EoLXon5w0g9AhQlr5kZTO_gBQ9TVE9AcQJuJu_Cw_9Y1Jw?e=OU2KLh

ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed leader in molecular diagnostics, is pleased to announce an exclusive distribution agreement with Riken Genesis Co., Ltd. (https://www.rikengenesis.jp/en.html). Under this partnership, Riken Genesis will promote and commercialize ABLD’s DeepChek® and UltraGene molecular assays across laboratories in Japan, further strengthening its diagnostics portfolio. Through this collaboration, Riken Genesis

REAL LIFE EXPERIENCE: The relevance of ultradeep sequencing for low HIV‐1 viral loads and proviruses in the clinical setting Webinar from Tuesday November 19, 2024 – 4pm CEST https://ablsa-my.sharepoint.com/:f:/p/matthieu_barralon/EoLXon5w0g9AhQlr5kZTO_gBQ9TVE9AcQJuJu_Cw_9Y1Jw?e=OU2KLh

NEWBURYPORT, MA, UNITED STATES, September 23, 2024 /EINPresswire.com/ — AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, is pleased to announce today the execution of a co-marketing agreement to co-promote in the USA Next Generation

The relevance of ultradeep sequencing for low HIV-1 viral loads and proviruses in the clinical setting Alizée Foury 1 2, Aline Saunier 2, Audrey Taverniers 2, Nathalie Pinet 2, Thomas Josse 2, Eliette Jeanmaire 3, Caroline Emilie 3, Evelyne Schvoerer 2 4, Cédric Hartard 2 4 Abstract Improving the therapeutic management of HIV-positive persons is a major public health issue and includes better detection of drug resistance mutations (DRMs). The aim of this study was

WOIPPY, FRANCE, August 21, 2024 /EINPresswire.com/ — ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories today announced its DeepChek® offer for SARS-CoV-2 Assays & Software, able to identify, to distinguish and to monitor circulating SARS-CoV-2 variants, indicative of COVID-19 infection and related epidemics, has

WOIPPY, FRANCE, July 16, 2024 /EINPresswire.com/ — ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the execution of an exclusive distribution agreement to confer to Interlux OÜ (https://www.linkedin.com/company/interlux-estonia/ ) the rights to promote and commercialize ABLD assays and software

Management of the APOBEC Mutations through the DeepChek-HIV Proviral DNA Genotyping Assays & Software OVERVIEW & USERS EXPERIENCE Webinar from Thursday June 13, 2024 – 4pm CEST